LUMAKRAS (sotorasib)
ORAL TREATMENTS FOR NON-SMALL CELL LUNG CANCER · NON-SMALL CELL LUNG CANCER WITH KRAS G12C MUTATION ·+1
AMGEN
Drug class
Antineoplastic - RAS Protein Inhibitors
Antineoplastic RAS protein inhibitors are a specialized class of targeted antineoplastic agents designed to bind and disrupt hyperactive RAS family GTPases, most notably mutated KRAS variants. Read more about Antineoplastic - RAS Protein Inhibitors
3 drugs in this class 3 manufacturers
Drugs in Antineoplastic - RAS Protein Inhibitors
KRAZATI (adagrasib)
ORAL TREATMENTS FOR NON-SMALL CELL LUNG CANCER · NON-SMALL CELL LUNG CANCER WITH KRAS G12C MUTATION
MIRATI THERAPEU
RASONQUE (daraxonrasib)
ANTINEOPLASTIC - RAS PROTEIN INHIBITORS · ADENOCARCINOMA OF PANCREAS
REVOLUTION MEDI
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - RAS Protein Inhibitors preselected. Add indication or manufacturer filters there.
Antineoplastic RAS protein inhibitors are a specialized class of targeted antineoplastic agents designed to bind and disrupt hyperactive RAS family GTPases, most notably mutated KRAS variants.
By selectively locking the oncoprotein in an inactive conformation or preventing downstream signaling through the MAPK/ERK pathway, these agents suppress oncogenic cellular proliferation and survival.
Clinically, members of this class are primarily approved and investigated for advanced or metastatic solid tumors characterized by specific RAS driver mutations, including non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
-
nih.gov
Antineoplastic RAS protein inhibitors are a specialized class of targeted antineoplastic agents designed to bind and disrupt hyperactive RAS family GTPases, most notably mutated KRAS variants By selectively locking the oncoprotein in an inactive conformation or preventing downstream signaling through the MAPK/ERK pathway, these agents suppress oncogenic cellular proliferation and survival
-
nih.gov
Antineoplastic RAS protein inhibitors are a specialized class of targeted antineoplastic agents designed to bind and disrupt hyperactive RAS family GTPases, most notably mutated KRAS variants By selectively locking the oncoprotein in an inactive conformation or preventing downstream signaling through the MAPK/ERK pathway, these agents suppress oncogenic cellular proliferation and survival
-
researchgate.net
By selectively locking the oncoprotein in an inactive conformation or preventing downstream signaling through the MAPK/ERK pathway, these agents suppress oncogenic cellular proliferation and survival Clinically, members of this class are primarily approved and investigated for advanced or metastatic solid tumors characterized by specific RAS driver mutations, including non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
-
biorxiv.org
Clinically, members of this class are primarily approved and investigated for advanced or metastatic solid tumors characterized by specific RAS driver mutations, including non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.